- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 207/16
Total number of patents in this class: 1184
10-year publication summary
|
82
|
87
|
76
|
85
|
103
|
84
|
60
|
67
|
56
|
54
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7941 |
27 |
| Bristol-myers Squibb Company | 4867 |
17 |
| Givaudan SA | 1889 |
16 |
| Novartis AG | 10730 |
15 |
| Epics Therapeutics | 19 |
15 |
| Hoffmann-La Roche Inc. | 3461 |
13 |
| Life Technologies Corporation | 3320 |
12 |
| President and Fellows of Harvard College | 5995 |
12 |
| Omeros Corporation | 308 |
12 |
| ThermoLife International, LLC | 128 |
12 |
| Xwpharma Ltd. | 58 |
11 |
| Aichi Steel Corporation | 383 |
10 |
| Biogen MA Inc. | 906 |
10 |
| Cytokinetics, Inc. | 280 |
10 |
| Tokushima University | 217 |
9 |
| The Regents of the University of California | 20059 |
8 |
| Amgen Inc. | 4106 |
8 |
| Abbvie Inc. | 1800 |
8 |
| Astellas Pharma Inc. | 1083 |
8 |
| Enanta Pharmaceuticals, Inc. | 429 |
8 |
| Other owners | 943 |